$20MSeries B, 4 September 2025
Funds the BOOM-IBD2 pivotal trial of neuromodulation in ulcerative colitis.
- Amount
- $20M
- Stage
- Series B
- Announced
- 4 September 2025
- Lead
- Arboretum Ventures
- Other investors
- Hatteras Venture Partners
- Use of funds
- Funds the BOOM-IBD2 pivotal trial of neuromodulation in ulcerative colitis.
- Checked
- Announced by the company
- Sources
- Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowe businesswire.com
Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowe news.google.com